STAT+: Pharmalittle: We’re reading about upbeat results for a Duchenne drug, Takeda layoffs, and much more

Rise and shine, everyone, another busy day is on the way. And it is getting off to a pleasant start here on the Pharmalot campus, where clear blue skies and comfy breezes are greeting us.

Who could ask for anything more? Actually, we could — it is time to reheat the kettle for another cuppa stimulation.

Our choice today is apple hibiscus. And here is a helpful tip — a teaspoon of honey enhances the flavors splendidly.

Of course, you are invited to join us. For the full experience, we are now hawking replicas —  take a look .

Meanwhile, here are a few tidbits to help you along. As always, do keep in touch.

We appreciate feedback, criticism, and tips. … Biogen reported mixed results from a mid-stage clinical trial investigating a treatment for Alzheimer’s disease that targets the protein tau that, like the better-known amyloid, is toxic to neurons and is believed to play a role in the cognitive decline of patients with the disease , STAT says.